[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)

BHVN : 14.32 (-2.25%)
Biohaven Announces Scientific Leadership Transitions

NEW HAVEN, Conn. , July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation...

BHVN : 14.32 (-2.25%)
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

NEW HAVEN, Conn. , June 30, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing...

BHVN : 14.32 (-2.25%)
Stock Indexes Finish Sharply Higher as Tech Soars

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.25%. September E-mini...

GOOGL : 319.74 (+0.65%)
AVGO : 381.92 (-2.69%)
VZ : 46.38 (+5.84%)
AXON : 502.34 (+2.12%)
$IUXX : 28,128.34 (-1.15%)
ASML : 1,757.09 (-2.55%)
MLM : 559.60 (+2.33%)
ZNU26 : 108-105s (+0.22%)
IRDM : 45.78 (-3.90%)
ESU26 : 7,447.50s (+0.03%)
T : 24.13 (+5.10%)
STX : 851.69 (-6.75%)
Stock Indexes Push Higher as Megacap Tech Stocks Rally

The S&P 500 Index ($SPX ) (SPY ) is up +0.73% today; the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.08%. September E-mini S&P futures...

GOOGL : 319.74 (+0.65%)
AAPL : 333.02 (+3.53%)
SNDK : 1,436.56 (-10.79%)
MLM : 559.60 (+2.33%)
TSLA : 313.03 (-2.08%)
AMD : 521.95 (-3.29%)
RBLX : 47.55 (unch)
DOCS : 20.42 (-0.15%)
SPY : 738.93 (+0.10%)
META : 595.19 (-1.80%)
ADSK : 209.75 (+2.19%)
MU : 920.95 (-6.99%)
Stock Indexes Supported by Strength in Megacap Tech Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.59%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.67%. September E-mini S&P futures...

GOOGL : 319.74 (+0.65%)
AAPL : 333.02 (+3.53%)
INTU : 296.33 (+5.26%)
SNDK : 1,436.56 (-10.79%)
DDOG : 246.86 (+1.01%)
AXON : 502.34 (+2.12%)
TXN : 279.58 (-1.90%)
$IUXX : 28,128.34 (-1.15%)
MLM : 559.60 (+2.33%)
ZNU26 : 108-105s (+0.22%)
MSFT : 381.70 (+0.03%)
IRDM : 45.78 (-3.90%)
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

NEW HAVEN, Conn. , June 29, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300...

BHVN : 14.32 (-2.25%)
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

NEW HAVEN, Conn. , June 1, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 14.32 (-2.25%)
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

NEW HAVEN, Conn. , May 27, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

BHVN : 14.32 (-2.25%)
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

NEW HAVEN, Conn. , May 26, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing...

BHVN : 14.32 (-2.25%)

Barchart Exclusives

A Roulette Wheel Has Taken Over S&P 500 Stocks. Here’s How Not to Lose Your House.
The SPDR S&P 500 Trust (SPY) a lot more like a roulette wheel that tends to have runs of consecutive patterns coming up. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.